Targeting epidermal growth factor receptor—are we missing the mark?
- 1 July 2003
- journal article
- review article
- Published by Elsevier in The Lancet
- Vol. 362 (9377), 62-64
- https://doi.org/10.1016/s0140-6736(03)13810-x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Severe acute interstitial pneumonia and gefitinibThe Lancet, 2003
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor TypesJournal of Clinical Oncology, 2002
- Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I TrialJournal of Clinical Oncology, 2002
- Influence of Unrecognized Molecular Heterogeneity on Randomized Clinical TrialsJournal of Clinical Oncology, 2002
- Pharmacodynamic Studies of the Epidermal Growth Factor Receptor Inhibitor ZD1839 in Skin From Cancer Patients: Histopathologic and Molecular Consequences of Receptor InhibitionJournal of Clinical Oncology, 2002
- Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapyCritical Reviews in Oncology/Hematology, 2001
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Anticancer AgentsDrugs, 2000